Introduction
============

The noncognitive behavioral and psychological symptoms of dementia (BPSD) displayed by patients suffering from Alzheimer disease (AD) include a heterogeneous spectrum of psychological reactions, psychiatric symptoms, and behaviors ([@b18-cia-3-719]). More than 90% of AD patients will experience at least one BPSD at some point during the course of their illness ([@b44-cia-3-719]; [@b22-cia-3-719]; [@b31-cia-3-719]). A community-based epidemiological study found that 61% of AD patients exhibited one or more BPSD in the past month and 61% of those with no baseline BPSD developed at least one symptom within 18 months ([@b31-cia-3-719]; [@b41-cia-3-719]). In a nursing home study a baseline prevalence of 76%, a two-year prevalence of 82%, and an annual incidence of 64% was detected ([@b2-cia-3-719]).

BPSD are a major problem for patients and their caregivers. They are considered one of the strongest predictors for institutionalization of demented patients ([@b7-cia-3-719]; [@b40-cia-3-719]; [@b37-cia-3-719]; [@b23-cia-3-719]; [@b47-cia-3-719]; [@b43-cia-3-719]); a prominent risk factor for caregiver burden and psychological morbidity ([@b28-cia-3-719]; [@b21-cia-3-719]; [@b23-cia-3-719]; [@b34-cia-3-719]); a significant obstacle in achieving adequate medical management for other health conditions ([@b6-cia-3-719]; [@b4-cia-3-719]); and a common cause of stress leading to staff burnout and subsequent turnover in institutional settings ([@b32-cia-3-719]).

The traditional pharmacological management of BPSD has significant morbidity including extrapyramidal signs and symptoms, gait abnormalities, sedation, an increased risk of falls and fractures, incidence of delirium, cerebrovascular events, and death ([@b12-cia-3-719]; [@b8-cia-3-719], [@b11-cia-3-719]; [@b3-cia-3-719]). An agent specific for AD that can treat BPSD with fewer side effects is highly desirable. Currently ChEIs are the standard of care for the treatment of cognitive deficit in patients with AD ([@b15-cia-3-719]; [@b3-cia-3-719]). Compared to alternatives, they are considered to have a more acceptable side effect profile ([@b3-cia-3-719]). Over the past decade, their potential role as psychotropic agents has been investigated in a variety of basic and clinical studies, which have suggested that the central cholinergic deficit associated with AD may be causative for the cognitive deterioration and the neuropsychiatric manifestations of AD ([@b27-cia-3-719]; [@b12-cia-3-719], [@b13-cia-3-719]; [@b11-cia-3-719]; [@b5-cia-3-719]). Previously, evaluating the use of ChEIs in managing BPSD has been reported in a meta-analysis by [@b48-cia-3-719] which included published trials of ChEIs up to 2001. Trinh included patients with mild-moderate AD only and included studies which used metrifonate, which is no longer available for the treatment of AD. However, since the publication of Trinh meta-analysis, numerous new trials have been published that investigated further the role of ChEIs as a psychotherapeutic agent in AD. The aim of our study was to systematically review the available literature and examine the therapeutic role of the currently available ChEIs in decreasing the burden of BPSD among patients with any stage of AD living in any clinical setting.

Methods
=======

Search strategies
-----------------

We searched MEDLINE from 1966 to 2007, Cochrane Collaboration Registry for Randomized Controlled Trials (RCT) from 1966 to 2007 and CINAHL from 1982 to 2007, using the following search terms: Alzheimer's disease, dementia, donepezil, rivastigmine, galantamine, cholinesterase inhibitors and behavioral and psychological symptoms. We limited our search to the English language, full text, published articles and human studies. We also retrieved relevant references of included studies for our search.

Selection criteria
------------------

The main goal of our systematic evidence review (SER) was to evaluate the efficacy of the currently available ChEIs in treating BPSD in patients with AD. Thus, we included only RCTs that evaluated the efficacy of any of the three FDA-approved and commonly used ChEIs (donepezil, rivastigmine, galantamine). We also included only studies that measured the BPSD with the Neuropsychiatric Inventory (NPI) among patients with any stage of AD living in any clinical setting. We selected NPI as the main outcome measure because it is considered by many investigators as the standard method to measure BPSD. The NPI is an informant-based structured interview with acceptable psychometric properties ([@b10-cia-3-719]; [@b9-cia-3-719]; [@b53-cia-3-719]; [@b39-cia-3-719]). Higher scores indicate higher frequency and severity of BPSD and a positive change from baseline reflects worsening symptoms ([@b10-cia-3-719]). We excluded pre and post studies and randomized controlled trials involving patients other than AD. Studies which were not placebo-controlled were also excluded from our SER.

Critical appraisal
------------------

Using the USPSTF critical appraisal method for quality assessment, we critically appraised the studies and included those with an attrition rate of less than 40%, a concealed measurement of the outcomes, and intention to treat analysis of the collected data.

Data abstraction
----------------

Three reviewers (AA, MB, NC) independently searched for the articles and abstracted data from each study that met our inclusion criteria into predefined evidence tables, that included: citation, total number of randomized patients, baseline demographic data (age, gender, educational level), mean Mini-Mental Status Examination score (MMSE), setting, duration of studies, drug used in studies, attrition rate, mean total NPI score, mean change from baseline of the total NPI score for both the treatment and placebo groups, and the level of significance for the mean difference in NPI between the two groups.

Quantitative data synthesis
---------------------------

We used Review Manager Software Version 4.2.1 (<http://www.cc-ims.net/RevMan>; Plone Foundation, Houston, TX, USA) to calculate the effect size and confidence interval (CI) of each individual study and the combined results. The effect size is the difference in the change of the total NPI score from baseline between the treatment and the placebo groups divided by the pooled standard deviation. In addition, we were also interested in identifying any potential confounder for the effect of ChEIs on BPSD such as disease stage and specific drug. Thus, we conducted a series of sensitivity analyses that combined data from the studies using similar inclusion criteria and interventions. Authors were also contacted for the data not reported or missing in the studies. After testing the heterogeneity of included trials, we primarily used a random effect model to combine the results of included studies. Other factors which were considered when carrying out the meta-analysis were sources of variation, such as sample sizes, dosing regimens, differences between treatment durations and routes of administration. Confounding variables would be MMSE scores or stage of symptom and age of the patients. Variations such as these would impact effect sizes, but as long as these effect sizes are in the same direction, whether negative or positive, a reliable effect would be evident.

Results
=======

Review flow
-----------

Our search strategies yield a total of 105 potentially relevant RCTs for retrieval. sixteen studies were excluded as they were not placebo-controlled trials and 27 studies were further excluded as they were open label, subgroup analyses or duplicate studies. Out of remaining 62 studies, 50 studies were excluded as they failed to meet the inclusion criteria. Finally, 12 randomized controlled trials (RCTs) met the inclusion criteria for our SER (see [Tables 1](#t1-cia-3-719){ref-type="table"} and [2](#t2-cia-3-719){ref-type="table"}) and only nine studies provided complete data to conduct the meta-analysis.

Study characteristics
---------------------

As demonstrated in [Tables 1](#t1-cia-3-719){ref-type="table"} and [2](#t2-cia-3-719){ref-type="table"}, the included studies were conducted among a heterogeneous group of participants with mild to severe cognitive deficits with a mean MMSE score ranging from 6.1 to 21. The mean difference of the primary outcome measure was not reported in three studies, which were therefore excluded from the meta-analysis. Five studies were conducted in outpatient settings, two in nursing homes, four in community and residential settings together, and one study did not report the clinical setting. Nine studies compared donepezil, two compared galantamine and one compared rivastigmine with placebos. The length of the studies varied from 3 to 12 months. The target dose of donepezil was 10 mg per day; that of galantamine varied from 16 to 24 mg daily; and rivastigmine was administered as either a capsule or a skin patch with target doses of 3--12 mg and 20 cm^2^ patches per day, respectively.

The mean age of the participants ranged from 72.5 to 85.7 years and the percentage of female participants ranged from 56.5% to 84.5%. Education level was reported in only one study and was 9.9 years. NPI was used as primary outcome measure in only two studies ([@b45-cia-3-719]; [@b24-cia-3-719]) and the secondary outcome measure in nine studies for the assessment of BPSD. The mean baseline NPI score ranged from 9.20 to 23.65. Two different versions of the NPI (10-item scale with score ranges from 0 to 120 points versus 12-item scale with score ranges from 0 to 144) were used. Baseline total NPI score was higher in the five studies that evaluated moderate to severe AD (15.1, 19.30, 19.55, 21.0 and 23.65) in comparison to the four studies which evaluated mild to moderate AD (9.2, 11.9, 13.05, 14.3).

Quantitative data analyses
--------------------------

The studies were not homogenous and therefore, we used the random effect model to combine their results and reported the standard mean difference (SMD). However, we have also reported the result from the fixed effect model and reported the weighted mean difference (WMD) for comparison with other reported meta-analyses (See [Figure 1](#f1-cia-3-719){ref-type="fig"}).

Patients receiving ChEIs (donepezil, rivastigmine or galantamine) improved the total NPI score when compared to the placebo with a SMD between the two groups of −0.10 (95% CI: −0.18, −0.01) and a WMD of −1.38 (95% CI: −2.20, −0.46). Combining only the results of homogenous studies, for example, those conducted among patients with mild-moderate AD showed that the SMD between the two groups was −0.16 (95% CI: −0.28, −0.03) and the WMD was −1.92 (95% CI: −3.18, −0.66) (see [Figure 2](#f2-cia-3-719){ref-type="fig"}).

When results of studies that included patients with moderate-severe AD were evaluated, the impact of ChEIs was not statistically significant anymore with a SMD of −0.06 (95% CI: −0.17, 0.05) and a WMD of −0.77(95% CI: −2.12, 0.57) (see [Figure 3](#f3-cia-3-719){ref-type="fig"}).

Looking at the effect of each of the three ChEIs separately, we found that the SMD between galantamine and placebo (two studies) was −1.65 (95% CI: −3.10, −0.19), between donepezil and placebo (6 studies) was −1.76 (95% CI: −3.37, −0.15) and between rivastigmine and placebo (one study) was −0.55 (95% CI: −2.31, 1.21).

Data on the individual domains of the NPI was not available to conduct a meta-analysis, but two studies ([@b17-cia-3-719]; [@b45-cia-3-719]) reported that donepezil significantly improved depression/dysphoria and apathy, but only anxiety symptoms were improved in one trial and only agitation/aggression in the other.

Discussion
==========

Clinically relevant change in BPSD as measured by NPI
-----------------------------------------------------

Our meta-analysis found that in comparison to placebo, 3 to 12 months' treatment with ChEIs had positive effects on global BPSD scores with an effect size (SMD) of 0.10 and WMD of 1.38 NPI points. The challenge, however, is to determine the clinical significance of this effect size and whether such an effect can be translated into reducing patients' or caregivers' burden. Various clinical investigators have used different total NPI points to determine the clinical meaning of NPI total change score. [@b27-cia-3-719] decided that a reduction or improvement of at least 50% in the average baseline NPI scores, approximately nine points difference on the total NPI score, is considered a clinically relevant change. We compared our results to a similar study published by [@b48-cia-3-719]. This study evaluated the impact of ChEIs on behavioral symptoms in patients with mild-moderate AD. The authors found a WMD in improvement in NPI scores between all ChEIs (including metrifonate) and placebo of 1.72 (95% CI: 0.87--2.57). By comparison, our study found similar results as the Trinh study when results for a similar population were evaluated (WMD −1.92 for patients in a mild-moderate stage of dementia). However, our results suggest this difference in NPI scores does not extend to the moderate-severe population (WMD of −0.77 with 95% CI of −2.12 to +0.57). The efficacy of ChEIs (galantamine and rivastigmine) on BPSD in other types of dementia such as vascular dementia and Lowy body dementia has been evaluated in two other studies ([@b16-cia-3-719]; [@b33-cia-3-719]). Both controlled trials had similar results as our study with a difference in mean change from baseline between treatment and placebo group of 2.3 points on the total NPI score for the vascular dementia trial (baseline total NPI score = 11.8) and 3.8 for trial including patients with Lewy body dementia (baseline total NPI score = 21.7). To further compare the clinical significance of our meta-analysis, we looked at the results of trials that used the NPI to evaluate the efficacy of an atypical antipsychotic (olanzapine) in reducing BPSD among AD nursing home residents who had clinically significant levels of behavioral and psychological symptoms at baseline with a total NPI score of at least 44 points ([@b42-cia-3-719]). In comparison to placebo, the mean decline from baseline in total NPI score was 8.3 points among patients taking olanzapine for six weeks ([@b42-cia-3-719]). Although the ChEIs' trials did not specifically enroll patients with baseline behavioral and psychological symptoms, the difference in the NPI changes from baseline between olanzapine and placebo was much higher than what we detected in our meta-analysis.

The natural history of the BPSD
-------------------------------

Before evaluating the efficacy of ChEIs on BPSD, one must examine their natural history as measured by a specific instrument such as the NPI. In a cross-sectional study, community dwelling elderly patients with dementia had a total NPI mean score of 7.11(SD = 10.9) as compared to 0.76 (SD = 2.89) points of those with no dementia. In addition, the total score increased as dementia-related disability worsened, individuals with mild dementia had a mean total score on the NPI of 5.80 (SD = 12.5), those with moderate dementia had a mean score of 8.8 (SD = 11.10), and those with severe dementia had a mean score of 10.6 (SD = 17.0) ([@b30-cia-3-719]). The mean total NPI score increased dramatically, ie, 36.4 (SD = 24.5), among patients with moderate to severe dementia admitted to the hospital for the management of their disturbed behaviors ([@b26-cia-3-719]). The prevalence data provide an idea of the total NPI score range but they do not explain the fluctuating nature of BPSD. During any specified period of time certain behaviors or symptoms will emerge, others will cease, some deteriorate, and others will improve ([@b29-cia-3-719]; [@b14-cia-3-719]; [@b20-cia-3-719]; [@b2-cia-3-719]). This fluctuating pattern of BPSD must be accounted for when interpreting the efficacy of certain interventions. We are unaware of any study that tried to determine whether this fluctuating pattern occurred on daily, weekly, monthly, or yearly basis.

Limitations
-----------

Our study has some limitations. First, we restricted our review to BPSD measured by the NPI. We were concerned that including other measures would make it difficult to interpret the data. Nevertheless, the NPI is considered the current standard instrument to evaluate BPSD. We previously reviewed all RCTs of ChEIs that evaluated the efficacy of tacrine on BPSD and found similar results from trials using the Alzheimer's Disease Assessment Scale-Noncognitive symptoms (ADAS-noncog) ([@b11-cia-3-719]). Secondly, we did not include individual domains of the NPI in our analysis, which may have truncated our findings. There is lack of published data on each of these 12 domains, although two included trials ([@b46-cia-3-719]; [@b17-cia-3-719]) reported the effect on individual domains but did not produce data that could be combined for meta-analysis ([@b46-cia-3-719]; [@b17-cia-3-719]). As the effect of ChEIs are likely to be greater on some BPSD than others, we believe that evaluating the effects of cholinesterase inhibitors on individual domains may carry more clinical meaning than using the global scale which sums all the BPSD in one score. The third limitation is related to being unable to identify the difference in the proportion of responders between placebo and treatment groups. One trial ([@b45-cia-3-719]) with NPI as the primary outcome reported the difference in the percentage of patients who had worsening symptoms on the agitation domain (placebo 32%, donepezil 24%), but it only stated that no significant finding was detected in the other domains ([@b45-cia-3-719]). We agree with [@b35-cia-3-719] in regard to the advantage of using comparisons based on the resolution of target BPSD domains or even the total score of NPI (categorical approach) rather than the use of an absolute or relative change in total score in interpreting the clinical value of certain interventions targeting BPSD. Finally, our review could not determine if the ChEI's effects were due to stability of BPSD among the treatment group versus deterioration among the placebo group, or if their effects reflected a true improvement in treatment groups.

Research need
-------------

Our review found a statistically significant effect of ChEIs (donepezil, rivastigmine, and galantamine) on BPSD in AD patients. However, we could not interpret the clinical relevance of this finding. Given the heterogeneity of BPSD and the need to explore further the efficacy of ChEIs in managing BPSD, we need to have a more clinically focused evaluation method. This method could be accomplished by either conducting a new clinical trial (a very expensive and ethically challenging method because ChEIs are considered to be the current standard of care in AD) or a retrospective post-hoc analysis of individual data from the 12 clinical trials that we included in our meta-analysis. The analytic framework for the suggested study would stratify the participants into two groups based on their baseline NPI total score: the prevention strata; which would include individuals with low NPI scores (≤20) and crisis intervention strata; which would include individuals with high NPI scores (\>20). Although the NPI would still be the main assessment tool, the trial would evaluate the impact of ChEIs using the individual domain scores for the NPI and a categorical approach to identify responders. The primary outcome would be the proportion of responders after 3 to 6 months. The responders would be defined differently between the two strata: in the prevention strata, the responders would include any individual with at least a stable NPI domain score at the end of the study, whereas in the crisis strata, the responders would include any individual who had at least a 30% reduction in their domain score. The study might also include additional data from the two trials that tested rivastigmine efficacy in dementia with Lewy body and galantamine efficacy in vascular dementia. Using this methodology (categorical outcome and changes in domain score) would enable us to report the difference in proportion of items improved, worsened, emerged, and/or ceased between treatment and control groups, and thus, we would better understand the clinical meaning of positive effects. A detailed investigation of the effect of ChEIs on specific behaviors at different stages of illness may be beneficial. We await the results of an acute phase BPSD study using memantine (MAGD ISRCTN24953404) and studies on new drugs such as tarenflurbil ([@b49-cia-3-719]). Specific medical, supportive, social or psychological interventions in agitation require further evidence.

Conclusions
===========

Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) have consistently shown a statistically significant improvement on BPSD as measured by the NPI. However, the existing clinical relevance of these findings is unclear and the use of this class of medications for BPSD does not appear to produce the necessary effect to be considered as monotherapy of behavioral or psychological symptoms in patients with dementia.
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###### 

Baseline variables of the included studies

  Study              N      Mean age   \% Female   Education level (years)   Mean MMSE   Total NPI Score
  ------------------ ------ ---------- ----------- ------------------------- ----------- ------------------------
  [@b46-cia-3-719]   978    76         64          NR                        18          11.9 (10 items)
  [@b17-cia-3-719]   290    73.6       61          NR                        12          19.55 (12 items)
  [@b38-cia-3-719]   386    75         56.5        NR                        20          9.20 (10 items)
  [@b45-cia-3-719]   208    85.7       82.5        NR                        14          21.0 (12 items) NPI-NH
  [@b51-cia-3-719]   286    72.5       64          NR                        19          13.05 (10 items)
  [@b19-cia-3-719]   207    74.3       65          NR                        13.7        17.3 (12 items)
  [@b36-cia-3-719]   202    --         --          --                        --          --
  [@b1-cia-3-719]    566    --         59          NR                        --          --
  [@b24-cia-3-719]   96     80.9       60.5        NR                        21          14.30 (10 items)
  [@b52-cia-3-719]   248    84.9       76.5        NR                        6.1         19.30 (12 items)
  [@b50-cia-3-719]   1195   73.6       66.5        9.9                       16.5        14.75 (12 items)
  [@b25-cia-3-719]   259    84.6       84.5        NR                        8.1         23.65 (12 items)

**Abbreviations:** N, total number of subjects included in the study; NPI, neuropsychiatric Inventory; NPI-NH, neuropsychiatric inventory-nursing home; NR, not reported.

###### 

Evidence table for all included studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study              Countries                                                    Setting                 Drug                                   Length (months)   N      Mean difference   Intervention attrition rate, %   Placebo attrition rate, %
  ------------------ ------------------------------------------------------------ ----------------------- -------------------------------------- ----------------- ------ ----------------- -------------------------------- ---------------------------
  [@b46-cia-3-719]   USA                                                          Out-patient             Galantamine                            5                 770    −2.10 SS          22                               16

  [@b17-cia-3-719]   Canada, Australia, France                                    Out-patient             Donepezil                              6                 290    −5.65 SS          16                               14

  [@b38-cia-3-719]   USA, Canada, Britain, South Africa, Australia, New Zealand   Out-patient             Galantamine                            3                 386    −0.90 NS          33                               10

  [@b45-cia-3-719]   USA                                                          Nursing homes           Donepezil                              6                 208    2.60 NS           18                               26

  [@b51-cia-3-719]   Northern European countries                                  Out-patient             Donepezil                              12                286    −1.13 NS          33                               33

  [@b19-cia-3-719]   Canada, Australia, France, USA                               Community/Residential   Donepezil                              6                 207    NR                19                               11

  [@b36-cia-3-719]   Finland, Hungary, Denmark.                                   NR                      Donepezil                              6                 202    NR                NR                               NR

  [@b1-cia-3-719]    UK                                                           Community/Residential   Donepezil                              15                566    NR                11                               5

  [@b24-cia-3-719]   UK                                                           Out-patient             Donepezil                              6                 96     −6.2 SS           15                               18

  [@b52-cia-3-719]   Sweden                                                       Nursing Homes           Donepezil                              6                 248    −1.70 NS          26                               18

  [@b50-cia-3-719]   Sweden, USA, Germany, Switzerland                            Community/Residential   Rivastigmine (20 cm-patch) (capsule)   6                 1078   −0.60 NS\         20\                              12
                                                                                                                                                                          −0.50 NS          21                               

  [@b25-cia-3-719]   United Kingdom                                               Residential/Community   Donepezil                              3                 259    −0.22 NS          10                               14
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** MD, mean difference of change on total NPI score between placebo and treatment; NR, not reported; NS, not significant; SS, statistically significant.

**Note:** Negative values indicate greater improvement in symptoms in the active treatment group.
